Evidence map›Paper›PMID 40682047›Full record

ArticleJournal of nanobiotechnology2025

Rapid diagnostic imaging and targeted immunotoxin delivery in aggressive prostate cancer using CEACAM5-specific nanobodies.

Zhaoming Xiao, Jingbo Ma, Jinpeng Cen, Tao Xie, Liuhai Zheng, Guangwei Shi, Zhifen Li, Yang Li, Chengming Qu, Yuanqiao He and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. A high-affinity CEA-targeted nanobody forJournal of nanobiotechnology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Zhaoming Xiao *Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, 510500, China.
Jingbo Ma *Department of Critical Care Medicine, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital (the First Affiliated Hospital, Southern University of Science and Technology, the Second Clinical Medical College, Jinan University), Shenzhen, 518020, China.
Jinpeng Cen *Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Tao Xie *Department of Urology and Guangdong Key Laboratory of Urology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
Liuhai ZhengDepartment of Critical Care Medicine, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital (the First Affiliated Hospital, Southern University of Science and Technology, the Second Clinical Medical College, Jinan University), Shenzhen, 518020, China.
Guangwei ShiDepartment of Critical Care Medicine, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital (the First Affiliated Hospital, Southern University of Science and Technology, the Second Clinical Medical College, Jinan University), Shenzhen, 518020, China.
Zhifen LiSchool of Chemistry and Chemical Engineering, Shanxi Datong University, Datong, 037009, Shanxi, China.
Yang LiDepartment of Critical Care Medicine, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital (the First Affiliated Hospital, Southern University of Science and Technology, the Second Clinical Medical College, Jinan University), Shenzhen, 518020, China.
Chengming QuDepartment of Critical Care Medicine, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital (the First Affiliated Hospital, Southern University of Science and Technology, the Second Clinical Medical College, Jinan University), Shenzhen, 518020, China.
Yuanqiao HeCenter of Laboratory Animal Science, Nanchang University, Nanchang, 330031, China.
Chong WangDepartment of Urology and Guangdong Key Laboratory of Urology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
Jun XiaoDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Haibo JiangDepartment of Chemistry, Hong Kong University, Hong Kong, China.
Zhijie LiDepartment of Critical Care Medicine, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital (the First Affiliated Hospital, Southern University of Science and Technology, the Second Clinical Medical College, Jinan University), Shenzhen, 518020, China. li.zhijie@szhospital.com.
Jigang WangDepartment of Critical Care Medicine, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital (the First Affiliated Hospital, Southern University of Science and Technology, the Second Clinical Medical College, Jinan University), Shenzhen, 518020, China. jgwang@icmm.ac.cn.
Shan-Chao ZhaoDepartment of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, 510500, China. lulululu@smu.edu.cn.

Funding

National Key Research and Development Program of China 2023YFE0204500
6 · The paper itself

Abstract

Aggressive variant prostate cancer (AVPC) originates from metastatic prostate cancer (mPCa) following androgen receptor-targeted therapies, leading to diverse pathological subtypes, notably castration-resistant prostate cancer (CRPC). Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), is consistently expressed across AVPC phenotypes, including neuroendocrine prostate carcinoma (NEPC) and double-negative prostate carcinoma (DNPC), which are significant subtypes of CRPC, making it a promising therapeutic target. In this study, A high-affinity nanobody, B12, specific to CEACAM5, was discovered through phage library screening. B12 exhibited robust binding capabilities, enhanced tumor accumulation, and effective tissue penetration, facilitating rapid in vivo imaging of AVPC. The conjugation of B12 with PE38 to create the immunotoxin B12-PE38 showed significant anti-tumor activity in AVPC xenograft models, including one that mimics bone metastasis. When B12-PE38 was combined with docetaxel, it elicited enhanced tumor inhibitory effects, effectively inhibiting tumor progression. This study underscores CEACAM5 as a target for precise imaging and targeted therapy in AVPC, introducing novel diagnostic and therapeutic strategies for a disease that currently faces a dearth of effective treatment options due to the scarcity of well-defined targets.

Indexed as

Carcinoembryonic AntigenImmunotoxinsProstatic NeoplasmsSingle-Domain AntibodiesAnimalsCell Line, TumorDocetaxelGPI-Linked ProteinsHumansMaleMiceMice, NudeXenograft Model Antitumor AssaysCarcinoembryonic AntigenCEACAM5 protein, humanDocetaxelGPI-Linked ProteinsImmunotoxinsSingle-Domain AntibodiesAggressive variant prostate cancerCEACAM5ImmunotoxinNanobodiesPhenotype transformationRapid imaging

Identifiers

PMID40682047
PMCPMC12275256

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.